Search
Now showing items 1-10 of 11
Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA
(2020)
Background
Adverse mental health consequences of COVID-19, including anxiety and depression, have been widely predicted but not yet accurately measured. There are a range of physical health risk factors for COVID-19, but ...
Mood Homeostasis, Low Mood, and History of Depression in 2 Large Population Samples
(2020-04)
Importance Existing therapeutic options are insufficient to tackle the disease burden of depression, and new treatments are sorely needed. Defining new psychotherapeutic targets is challenging given the paucity of coherent ...
The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial
(2020-07)
Introduction:Major depressive disorder (MDD) is a common affective disorder. Currently established pharmacotherapies lack rapid clinical response, thereby limiting their ability to bring instant relief to patients. A series ...
A Structural Brain Network of Genetic Vulnerability to Psychiatric Illness
(2020-05)
Psychiatry is undergoing a paradigm shift from the acceptance of distinct diagnoses to a representation of psychiatric illness that crosses diagnostic boundaries. How this transition is supported by a shared neurobiology ...
Longitudinal cognitive performance in patients with Bipolar Disorder
(2020-01)
Commentary: Neurocognitive impairments are a rather common occurrence in euthymic Bipolar Disorder (BD) patients. Understanding the degree of longitudinal stability of these deficits is vital in the management and treatment ...
Antidepressants plus benzodiazepines in major depressive disorder: a clinical dilemma with no recent answers from research
(2020-10)
Comorbid anxiety symptoms are common in depression, and adding benzodiazepines to antidepressant treatment may seem a rational clinical solution. Benzodiazepines also have potential to reduce the initial anxiety that may ...
How effective is augmentation with psychotherapy as a next-step option for treatment-resistant depression?
(2020-08)
Determining the optimum next-step treatment for the numerous patients with depression who do not adequately respond to an initial trial of medication remains a source of uncertainty in clinical practice. Although a number ...
Are benzodiazepines effective in treating catatonia?
(2020-12)
Establishing an evidence base for the clinical management of catatonia is made difficult by the heterogeneous nature of the condition and the limited understanding of its pathophysiology. Benzodiazepines are a mainstay of ...
Can we prevent seasonal affective disorder (SAD) with melatonergic agents?
(2020-06)
Seasonal affective disorder (SAD) is a recurrent form of major depression, particularly occurring in the winter months with a generally spontaneous remission in spring/summer. The predictable nature of this condition ...
Can dietary supplements maintain cognition in mid- to late-life?
(2020-12)
Cognitive health, and prevention of its decline to dementia, has risen in prominence with a corresponding exploration of modifiable risk factors to prevent a decline in cognitive health with age. This commentary discusses ...